The evaluation of early embryonic neurogenesis after exposure to the genotoxic agent 5-bromo-2′-deoxyuridine in mice

NeuroToxicology

Volumn 28, Issue 4, 2007, Pages 780-789

  Kuwagata, Makiko ^a,b   Ogawa, Tetsuo ^b   Nagata, Tomoko ^a   Shioda, Seiji ^b  

^a HATANO RESEARCH INSTITUTE   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BrdU; Cell death; Developmental neurotoxicity; Embryonic neurogenesis; Phosphorylated histone 3; Proliferation of embryonic stem cell

Indexed keywords

BROXURIDINE; HISTONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS STRIATUM; FETUS; GENOTOXICITY; GESTATIONAL AGE; HISTOPATHOLOGY; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; METAPHASE; MITOSIS; MOUSE; NEOCORTEX; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY; SUBSTANTIA NIGRA;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BROMODEOXYURIDINE; CELL DEATH; CELL PROLIFERATION; EMBRYO; FEMALE; IN SITU NICK-END LABELING; MICE; MICE, INBRED C57BL; NEURONS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; STEM CELLS;

MUS; RATTUS;

EID: 34447324614     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2006.07.017     Document Type: Article

References (44)

1. Artlich A., Moller J., Tschakaloff A., Schwinger E., Kruse K., and Gortner L. Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia-neonatal and infantile course. Eur J Pediatr 153 (1994) 488-491
2. Avale M.E., Falzone T.L., Gelman D.M., Low M.J., Grandy D.K., and Rubinstein M. The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder. Mol Psychiatry 9 (2004) 718-726
3. Bacon Y., Ooi A., Kerr S., Shaw-Andrews L., Winchester L., Breeds S., et al. Screening for novel ENU-induced rhythm, entrainment and activity mutants. Genes Brain Behav 3 (2004) 196-205
4. Barkley R.A. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18 (1977) 137-165
5. Bartley J., Soltau T., Wimborne H., Kim S., Martin-Studdard A., Hess D., et al. BrdU-positive cells in the neonatal mouse hippocampus following hypoxic-ischemic brain injury. BMC Neurosci 6 (2005) 15
6. Bayer S., Altman J., Russo R., and Zhang X. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14 1 (1993) 83-144
7. Chadee D.N., Hendzel M.J., Tylipski C.P., Allis C.D., Bazett-Jones D.P., Wright J.A., et al. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem 274 (1999) 24914-24920
8. Chen Z., Kontonotas D., Friedmann D., Pitts-Kiefer A., Frederick J.R., Siman R., et al. Developmental status of neurons selectively vulnerable to rapidly triggered post-ischemic caspase activation. Neurosci Lett 376 (2005) 166-170
9. Cheung P., Tanner K.G., Cheung W.L., Sassone-Corsi P., Denu J.M., and Allis C.D. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 5 (2000) 905-915
10. Crofton K.M., Makris S.L., Sette W.F., Mendez E., and Raffaele K.C. A qualitative retrospective analysis of positive control data in developmental neurotoxicity studies. Neurotoxicol Teratol 26 (2004) 345-352
11. Davids E., Zhang K., Tarazi F.I., and Baldessarini R.J. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl) 160 (2002) 92-98
12. Davids E., Zhang K., Tarazi F.I., and Baldessarini R.J. Animal models of attention-deficit hyperactivity disorder. Brain Res Brain Res Rev 42 (2003) 1-21
13. Fiore M., Aloe L., Westenbroek C., Amendola T., Antonelli A., and Korf J. Bromodeoxyuridine and methylazoxymethanol exposure during brain development affects behavior in rats: consideration for a role of nerve growth factor and brain derived neurotrophic factor. Neurosci Lett 309 (2001) 113-116
14. Katayama K., Ueno M., Yamauchi H., Nagata T., Nakayama H., and Doi K. Ethylnitrosourea induces neural progenitor cell apoptosis after S-phase accumulation in a p53-dependent manner. Neurobiol Dis 18 (2005) 218-225
15. Keays D.A., and Nolan P.M. N-ethyl-N-nitrosourea mouse mutants in the dissection of behavioural and psychiatric disorders. Eur J Pharmacol 480 (2003) 205-217
16. Kolb B., Pedersen B., Ballermann M., Gibb R., and Whishaw I.Q. Embryonic and postnatal injections of bromodeoxyuridine produce age-dependent morphological and behavioral abnormalities. J Neurosci 19 (1999) 2337-2346
17. Kuwagata M., Muneoka K.T., Ogawa T., Takigawa M., and Nagao T. Locomotor hyperactivity following prenatal exposure to 5-bromo-2′-deoxyuridine: neurochemical and behavioral evidence of dopaminergic and serotonergic alterations. Toxicol Lett 152 (2004) 63-71
18. Kuwagata M., and Nagao T. Behavior and reproductive function of rat male offspring treated prenatally with 5-bromo-2′-deoxyuridine. Reprod Toxicol 12 (1998) 541-549
19. Kuwagata M., Ohmukai H., Ogawa T., and Nagata T. Hyperactivity induced by exposure to a prenatal genotoxic agent, BrdU, across rodent species,strain and gender. Soc Toxicol 1460 (2006) [abstract]
20. Kuwagata M., Saito Y., Usumi K., Ono H., and Nagao T. Disruption of brain development in male rats exposed prenatally to 5-bromo-2′-deoxyuridine. Congenit Anom (Kyoto) 41 (2001) 312-320
21. Laposa R.R., Henderson J.T., Xu E., and Wells P.G. Atm-null mice exhibit enhanced radiation-induced birth defects and a hybrid form of embryonic programmed cell death indicating a teratological suppressor function for ATM. FASEB J 18 (2004) 896-898
22. Leng A., Jongen-Relo A.L., Pothuizen H.H., and Feldon J. Effects of prenatal methylazoxymethanol acetate (MAM) treatment in rats on water maze performance. Behav Brain Res 161 (2005) 291-298
23. Linnet K.M., Dalsgaard S., Obel C., Wisborg K., Henriksen T.B., Rodriguez A., et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry 160 (2003) 1028-1040
24. Londei T., Misto R., Vismara C., and Leone V.G. Congenital brain damage spares the basic patterns of parental behavior in affected mice. Brain Res 677 (1995) 61-68
25. Miller M.W., and Nowakowski R.S. Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system. Brain Res 457 (1988) 44-52
26. Moore S.J., Turnpenny P., Quinn A., Glover S., Lloyd D.J., Montgomery T., et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37 (2000) 489-497
27. Morris S.M. The genetic toxicology of 5-bromodeoxyuridine in mammalian cells. Mutat Res 258 (1991) 161-188
28. Nagao T., Kuwagata M., and Saito Y. Effects of prenatal exposure to 5-bromo-2′-deoxyuridine on the developing brain and reproductive function in male mouse offspring. Reprod Toxicol 12 (1998) 477-487
29. Nagao T., Sato M., Kuwagata M., and Saito Y. Effects of prenatal exposure to 5-bromo-2′-deoxyuridine on reproductive function in male mouse offspring. Reprod Toxicol 11 (1997) 663-673
30. O'Shaughnessy D., and Boyes W. Testing for developmental neurotoxicity: session VII-A summary and research needs. Neurotoxicology 25 (2004) 511-514
31. Ogawa T., Kuwagata M., Muneoka K.T., and Shioda S. Neuropathological examination of fetal rat brain in the 5-bromo-2′-deoxyuridine-induced neurodevelopmental disorder model. Congenit Anom (Kyoto) 45 (2005) 14-20
32. Ogawa T., Kuwagata M., and Shioda S. Observation of catecholaminergic neurons in the fetal rat brain exposed to the genotoxic compound, 5-bromo-2′-deoxyuridine (BrdU). Soc Toxicol (2005) 988 [abstract]
33. Plane J.M., Liu R., Wang T.W., Silverstein F.S., and Parent J.M. Neonatal hypoxic-ischemic injury increases forebrain subventricular zone neurogenesis in the mouse. Neurobiol Dis 16 (2004) 585-595
34. Pliszka S.R., McCracken J.T., and Maas J.W. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35 (1996) 264-272
35. Rogan W.J., Gladen B.C., Hung K.L., Koong S.L., Shih L.Y., Taylor J.S., et al. Congenital poisoning by polychlorinated biphenyls and their contaminants in Taiwan. Science 241 (1988) 334-336
36. Sekerkova G., Ilijic E., and Mugnaini E. Bromodeoxyuridine administered during neurogenesis of the projection neurons causes cerebellar defects in rat. J Comp Neurol 470 (2004) 221-239
37. Soriano E., and Del Rio J.A. Simultaneous immunocytochemical visualization of bromodeoxyuridine and neural tissue antigens. J Histochem Cytochem 39 (1991) 255-263
38. Stromland K., Nordin V., Miller M., Akerstrom B., and Gillberg C. Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol 36 (1994) 351-356
39. Takahashi T., Goto T., Miyama S., Nowakowski R.S., and Caviness Jr. V.S. Sequence of neuron origin and neocortical laminar fate: relation to cell cycle of origin in the developing murine cerebral wall. J Neurosci 19 (1999) 10357-10371
40. Thapar A., Fowler T., Rice F., Scourfield J., van den Bree M., Thomas H., et al. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry 160 (2003) 1985-1989
41. Tonchev A.B., Yamashima T., Zhao L., and Okano H. Differential proliferative response in the postischemic hippocampus, temporal cortex, and olfactory bulb of young adult macaque monkeys. Glia 42 (2003) 209-224
42. Ueno M., Katayama K., Yasoshima A., Nakayama H., and Doi K. 5-Azacytidine (5AzC)-induced histopathological changes in the central nervous system of rat fetuses. Exp Toxicol Pathol 54 (2002) 91-96
43. Yamauchi H., Katayama K., Ueno M., Uetsuka K., Nakayama H., and Doi K. Involvement of p53 in 1-beta-d-arabinofuranosylcytosine-induced rat fetal brain lesions. Neurotoxicol Teratol 26 (2004) 579-586
44. Yolton K., Dietrich K., Auinger P., Lanphear B.P., and Hornung R. Exposure to environmental tobacco smoke and cognitive abilities among U.S. children and adolescents. Environ Health Perspect 113 (2005) 98-103